The financials
Vericel Corporation by the numbers
Vericel Corporation (VCEL) reported revenue of $68M in Q1 2026 (quarter ended March 31, 2026), up 30% from the same quarter a year earlier. That came with a gross margin of 72% and net loss of $6.3M. For the full year FY2025, revenue was $276M (+16% year on year) and net income $17M. Its largest product in 2026-Q2 was MACI Implants And Kits at $66M, 86% of the disclosed total, just ahead of Epicel at 14%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $68M | $53M | +30% |
| Gross profit | $49M | $36M | +36% |
| Operating income | −$8.1M | −$13M | n/a |
| Net income | −$6.3M | −$11M | n/a |
| Diluted EPS | −$0.12 | −$0.23 | n/a |
| Product | Revenue | Share |
|---|---|---|
| MACI Implants And Kits | $66M | 86% |
| Epicel | $10M | 14% |
| Biopsy Kits | $614K | 0.8% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $76.5M (+13%)
MACI Implants And Kits grew +23% year on yearBiopsy Kits -4.4% year on year
Segment Latestquarter on quarteryear on year
- MACI Implants And Kits$65.5M$65.5MQoQ +16%year on year +23%+16%+23%
- Epicel$10.4M$10.4MQoQ -4.4%year on year +21%-4.4%+21%
- Biopsy Kits$614.0K$614.0KQoQ +1.3%year on year -4.4%+1.3%-4.4%